{
  "actions": [
    {
      "acted_at": "2017-03-15", 
      "action_code": "10000", 
      "references": [], 
      "text": "Introduced in Senate", 
      "type": "action"
    }, 
    {
      "acted_at": "2017-03-15", 
      "action_code": "", 
      "committees": [
        "SSFI"
      ], 
      "references": [], 
      "status": "REFERRED", 
      "text": "Read twice and referred to the Committee on Finance.", 
      "type": "referral"
    }
  ], 
  "amendments": [], 
  "bill_id": "s637-115", 
  "bill_type": "s", 
  "by_request": false, 
  "committee_reports": [], 
  "committees": [
    {
      "activity": [
        "referral"
      ], 
      "committee": "Senate Finance", 
      "committee_id": "SSFI"
    }
  ], 
  "congress": "115", 
  "cosponsors": [
    {
      "bioguide_id": "B000944", 
      "district": null, 
      "name": "Brown, Sherrod", 
      "original_cosponsor": true, 
      "sponsored_at": "2017-03-15", 
      "state": "OH", 
      "title": "Sen", 
      "withdrawn_at": null
    }, 
    {
      "bioguide_id": "H001069", 
      "district": null, 
      "name": "Heitkamp, Heidi", 
      "original_cosponsor": true, 
      "sponsored_at": "2017-03-15", 
      "state": "ND", 
      "title": "Sen", 
      "withdrawn_at": null
    }, 
    {
      "bioguide_id": "T000464", 
      "district": null, 
      "name": "Tester, Jon", 
      "original_cosponsor": false, 
      "sponsored_at": "2017-03-22", 
      "state": "MT", 
      "title": "Sen", 
      "withdrawn_at": null
    }
  ], 
  "enacted_as": null, 
  "history": {
    "active": false, 
    "awaiting_signature": false, 
    "enacted": false, 
    "vetoed": false
  }, 
  "introduced_at": "2017-03-15", 
  "number": "637", 
  "official_title": "A bill to amend titles XI and XVIII of the Social Security Act to provide greater transparency of discounts provided by drug manufacturers.", 
  "popular_title": null, 
  "related_bills": [], 
  "short_title": "Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017", 
  "sponsor": {
    "bioguide_id": "W000779", 
    "district": null, 
    "name": "Wyden, Ron", 
    "state": "OR", 
    "title": "Sen", 
    "type": "person"
  }, 
  "status": "REFERRED", 
  "status_at": "2017-03-15", 
  "subjects": [
    "Government information and archives", 
    "Health", 
    "Health care costs and insurance", 
    "Inflation and prices", 
    "Medicare", 
    "Prescription drugs"
  ], 
  "subjects_top_term": "Health", 
  "summary": {
    "as": "Introduced in Senate", 
    "date": "2017-03-15T04:00:00Z", 
    "text": "Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 \n\nThis bill amends title XI (General Provisions) of the Social Security Act (SSAct) to\u00a0require the public\u00a0disclosure of certain information provided to the Department of Health and Human Services (HHS) by a pharmacy benefit manager (PBM)\u00a0that contracts with: (1) a prescription drug\u00a0plan (PDP) under Medicare or\u00a0Medicare Advantage (MA),\u00a0or (2) a qualified health benefits plan offered through an exchange established under the Patient Protection and Affordable Care Act.\u00a0Specifically, HHS must publish on its website, with respect to each PBM, information\u00a0regarding: (1) the amount and type of rebates and discounts negotiated by the PBM and the extent to which these rebates and discounts are passed on to the plan sponsor, and (2) the difference between the amount paid by the plan sponsor to the PBM and the amount paid by the PBM to pharmacies.\n\nAs a condition of participation as a contractor\u00a0under Medicare or MA, a PBM must pass\u00a0on to\u00a0a\u00a0PDP sponsor a minimum percentage, as established by HHS, of the amount of rebates and discounts negotiated by the PBM that are attributable to patient utilization under the plan.\n\nThe bill also\u00a0amends title XVIII (Medicare) of the SSAct to modify requirements\u00a0regarding enrollees' access to negotiated drug prices.\u00a0Current law requires\u00a0a PDP sponsor\u00a0to provide enrollees in Medicare\u00a0or MA\u00a0with access to negotiated\u00a0drug prices that\u00a0account for rebates and discounts. The bill requires\u00a0that, with respect to a covered drug,\u00a0a\u00a0negotiated price (or,\u00a0if necessary, an approximate negotiated price)\u00a0be provided at the point of sale."
  }, 
  "titles": [
    {
      "as": "introduced", 
      "is_for_portion": false, 
      "title": "Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017", 
      "type": "short"
    }, 
    {
      "as": "introduced", 
      "is_for_portion": false, 
      "title": "Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017", 
      "type": "short"
    }, 
    {
      "as": "introduced", 
      "is_for_portion": false, 
      "title": "A bill to amend titles XI and XVIII of the Social Security Act to provide greater transparency of discounts provided by drug manufacturers.", 
      "type": "official"
    }, 
    {
      "as": null, 
      "is_for_portion": false, 
      "title": "Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017", 
      "type": "display"
    }
  ], 
  "updated_at": "2017-09-11T02:39:42Z", 
  "url": "https://www.gpo.gov/fdsys/bulkdata/BILLSTATUS/115/s/BILLSTATUS-115s637.xml"
}